NYSE - Nasdaq Real Time Price USD

Colgate-Palmolive Company (CL)

88.97 +0.39 (+0.44%)
As of 3:43 PM EDT. Market Open.

Earnings Estimate

CURRENCY IN USD Current Qtr. (Mar 2024)Next Qtr. (Jun 2024)Current Year (2024)Next Year (2025)
No. of Analysts 16151919
Avg. Estimate 0.810.863.493.8
Low Estimate 0.760.843.383.69
High Estimate 0.860.893.533.97
Year Ago EPS 0.730.773.233.49

Revenue Estimate

CURRENCY IN USD Current Qtr. (Mar 2024)Next Qtr. (Jun 2024)Current Year (2024)Next Year (2025)
No. of Analysts 12121718
Avg. Estimate 4.96B4.99B20.15B21.02B
Low Estimate 4.91B4.93B19.91B20.71B
High Estimate 5.02B5.04B20.36B21.4B
Year Ago Sales 4.77B4.82B19.46B20.15B
Sales Growth (year/est) 3.90%3.40%3.60%4.30%

Earnings History

CURRENCY IN USD 3/31/2023 6/30/2023 9/30/2023 12/31/2023
EPS Est. 0.70.750.80.85
EPS Actual 0.730.770.860.87
Difference 0.030.020.060.02
Surprise % 4.30%2.70%7.50%2.40%

EPS Trend

CURRENCY IN USD Current Qtr. (Mar 2024)Next Qtr. (Jun 2024)Current Year (2024)Next Year (2025)
Current Estimate 0.810.863.493.8
7 Days Ago 0.810.863.493.8
30 Days Ago 0.810.863.493.8
60 Days Ago 0.750.793.223.51
90 Days Ago 0.820.863.473.77

EPS Revisions

CURRENCY IN USD Current Qtr. (Mar 2024)Next Qtr. (Jun 2024)Current Year (2024)Next Year (2025)
Up Last 7 Days 5--32
Up Last 30 Days 6254
Down Last 7 Days --------
Down Last 30 Days --12--

Growth Estimates

CURRENCY IN USD CLIndustrySectorS&P 500
Current Qtr. 11.00%----1.50%
Next Qtr. 11.70%----11.40%
Current Year 8.00%----5.20%
Next Year 8.90%----13.40%
Next 5 Years (per annum) 8.47%----11.09%
Past 5 Years (per annum) 2.42%------

Research Analysis

Analyst Price Targets

70.00 Low
91.44 Average
88.97 Current
103.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Upgrades & Downgrades

Maintains Citigroup: Buy to Buy 4/16/2024
Maintains Barclays: Equal-Weight to Equal-Weight 4/12/2024
Maintains Stifel: Buy to Buy 4/10/2024
Maintains Evercore ISI Group: Outperform to Outperform 4/8/2024
Maintains Morgan Stanley: Overweight to Overweight 1/29/2024
Maintains UBS: Buy to Buy 1/29/2024

Related Tickers